Helus Pharma, the commercial name for Cybin, reported its first-quarter fiscal 2027 results on August 14, and the release does something worth noticing beyond the standard cadence of enrollment updates and cash figures. Its two lead programs are each addressing a specific, practical barrier to adoption that has nothing to do with whether a serotonergic agonist can reduce depression or anxiety scores. HLP003 just reported a drug-interaction profile clean enough to support use alongside SSRIs and SNRIs. HLP004 gets patients ready for discharge in three hours. Read together, this is a company building around the two objections that determine whether a clinic, a payer, or a primary care physician actually adopts a psychedelic-class drug, not just whether the drug works in a controlled trial.
The SSRI problem, addressed directly
Nearly every psychedelic trial this desk has covered requires patients to taper off SSRIs, SNRIs, or other serotonergic medications before dosing, a real, practical barrier given how many patients with treatment-resistant depression are already on one of these drugs and may be reluctant or medically unable to stop. Helus completed a dedicated drug-drug interaction study for HLP003 and reported no meaningful pharmacokinetic interaction across six tested substrates, concluding a low likelihood of interaction with SSRIs and SNRIs specifically. The company is explicitly positioning HLP003 as an adjunctive MDD treatment, taken alongside existing antidepressant therapy rather than requiring a washout period first. If that positioning holds through later-stage review, it removes one of the more consistent access barriers this desk has tracked across the entire psychedelic drug class, the population most likely to need a next-line treatment is also the population most likely to already be on a drug that current protocols require them to stop.
The session-length problem, addressed differently
HLP004, Helus’s GAD candidate, reports acute effects lasting roughly 90 minutes, with all Phase 1 participants at the 30 milligram dose ready for discharge within three hours. That is a fraction of the six-to-eight-hour monitored sessions this desk has documented across classic psilocybin and LSD protocols, Compass’s COMP360, Definium’s DT120 among them. Session length is not a cosmetic detail. It is a direct input into per-patient clinic cost, provider throughput, and ultimately how a payer or health system models the economics of offering this class of treatment at scale. A three-hour session structurally changes that math in a way a six-to-eight-hour one does not, independent of whether the underlying efficacy data holds up.
What the underlying efficacy data actually shows, read carefully
HLP003’s previously reported Phase 2 data, recapped in this release, is genuinely strong on its face: a 23-point MADRS reduction at 12 months following two 16 milligram doses three weeks apart, with a 100 percent response rate and 71 percent remission rate against a remission benchmark of 10 or below. Those are large numbers, and this desk has learned across a year of covering this sector to ask the same question of every headline figure: what population is the denominator. This release does not specify whether the 100 percent response and 71 percent remission rates reflect the full enrolled population, an intent-to-treat analysis, or a completer subset, the same distinction that mattered considerably when this desk read Compass’s own durability data earlier this year. HLP004’s Phase 2 numbers are more modest and more precisely reported, a roughly 10-point HAM-A improvement over standard of care at six weeks, with 67 percent responders and 39 percent remission in the pooled population sustained through at least six months, figures worth taking at face value but still short of the standalone confirmatory data a pivotal trial would need to produce.
Leadership change and the balance sheet
Helus appointed Michael Halstead, formerly president of Intra-Cellular Therapies, as CEO, a company that successfully commercialized Caplyta, an atypical antipsychotic, giving Halstead direct experience taking a CNS drug through the transition this company is now approaching with HLP003. The quarter’s financials show the cost of that approach: net loss nearly doubled year over year, from $24.6 million to $47.8 million, driven by the simultaneous advancement of three Phase 3-adjacent programs, APPROACH, EMBRACE, and EXTEND. A $50 million offering completed in June brought cash to $166.4 million, a real runway but one that will need watching against a burn rate that has grown considerably faster than revenue, since there is none yet.
The caveats
None of HLP003’s or HLP004’s data has been independently peer-reviewed or reviewed by FDA at time of this release, and the company’s own materials carry the standard forward-looking caveats about timeline risk that every clinical-stage sponsor attaches to its guidance. The DDI study addressing SSRI and SNRI interaction is a pharmacokinetic finding, no meaningful effect on plasma levels of tested substrates, not a clinical trial demonstrating that adjunctive use is actually safe and effective in practice; that remains to be shown in a dedicated study. And HLP004’s rapid-discharge data comes from a Phase 1 study at a single dose level, a much smaller and earlier evidentiary base than the company’s own promotional framing might suggest on a quick read.
The frame
Most of this desk’s coverage of psychedelic drug development treats efficacy and safety data as the central story, and durability, blinding, and effect-size questions as the things worth scrutinizing underneath it. This release is a reminder that a molecule with strong efficacy data can still fail to reach patients if it requires stopping a medication they depend on, or if the session length makes it economically impractical for a health system to offer. Helus is building its two lead programs specifically around removing those two barriers, not around claiming a bigger effect size than its competitors. Whether that strategy pays off depends on whether HLP003’s Phase 3 data, expected in the fourth quarter, and HLP004’s next study, designed by the end of the third quarter, actually confirm what the early numbers suggest. But the strategic logic itself, address the access barriers a payer or clinic would actually raise, not just the ones a review article would, is a genuinely different bet than most of this sector has been making.